1. 1869 Disease characteristics of subgroup patients treated with everolimus + exemestane for <12 months, ≥12 to <18months, and ≥18 months - Results of the 3rd interim analysis of the non-interventional trial BRAWO. (September 2015) Authors: Lüftner, D.; Grischke, E.M.; Fasching, P.; Decker, T.; Schneeweiss, A.; Uleer, C.; Foerster, F.; Wimberger, P.; Kluth-Pepper, B.; Schubert, J.; Bloch, W.; Tesch, H.; Schuetz, F.; Jackisch, C. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S288 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Reduction of Serious Adverse Events (SAE) under palbociclib treatment in patients using an interactive eHealth system. (October 2020) Authors: Schmidt, M.; Degenhardt, T.; Fasching, P.A.; Lüftner, D.; Müller, V.; Thomssen, C.; Schem, C.; Witzel, I.; Decker, T.; Tesch, H.; Kümmel, S.; Uleer, C.; Würstlein, R.; Hoffmann, O.; Warm, M.; Marschner, N.; Kates, R.E.; Schumacher, J.; Harbeck, N. Journal: European journal of cancer Issue: Volume 138(2020)Supplement 1 Page Start: S68 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗